David Cole to Cancer Vaccines
This is a "connection" page, showing publications David Cole has written about Cancer Vaccines.
Connection Strength
1.971
-
Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol. 2017 04 07; 10(1):82.
Score: 0.539
-
Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination. Cancer Immunol Immunother. 2010 Mar; 59(3):341-53.
Score: 0.323
-
Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol. 2009 Feb 15; 182(4):2030-40.
Score: 0.306
-
Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination. Clin Cancer Res. 1999 May; 5(5):1173-82.
Score: 0.155
-
Characterization of a sustained-release delivery system for combined cytokine/peptide vaccination using a poly-N-acetyl glucosamine-based polymer matrix. Clin Cancer Res. 1997 Jun; 3(6):867-73.
Score: 0.136
-
Melanoma-associated tumor antigens and their clinical relevance to immunotherapy. Semin Oncol. 1996 Dec; 23(6):754-8.
Score: 0.131
-
A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg. 2013 Dec; 258(6):879-86.
Score: 0.107
-
A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma. Clin Colorectal Cancer. 2006 Jan; 5(5):368-71.
Score: 0.062
-
Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J Immunother. 2005 May-Jun; 28(3):220-8.
Score: 0.059
-
Paracrine release of IL-12 stimulates IFN-gamma production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine. J Immunol. 2004 May 01; 172(9):5159-67.
Score: 0.055
-
Mechanisms of enhanced antigen-specific T cell response following vaccination with a novel peptide-based cancer vaccine and systemic interleukin-2 (IL-2). Vaccine. 2003 Jun 02; 21(19-20):2318-28.
Score: 0.052
-
Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response. J Immunother. 2001 Sep-Oct; 24(5):420-9.
Score: 0.046